Literature DB >> 19931242

The interaction of angiocidin with tissue transglutaminase.

Darryl Z L'Heureux1, Vicki L Rothman, George P Tuszynski.   

Abstract

Angiocidin, a matrix bound and tumor associated protein, has been shown to inhibit tumor progression and angiogenesis. We previously demonstrated that angiocidin binds to thrombospondin-1 and alpha2beta1 integrin. We now show that angiocidin binds and is a preferred substrate for tissue transglutaminase-2 (tTgase). Angiocidin bound tTgase saturably with a Kd of 26 nM, while an angiocidin deletion mutant missing the matrix binding domain of angiocidin failed to bind tTgase. tTgase colocalized with angiocidin on endothelial cells. tTgase bound anti-angiocidin immunoprecipitates of endothelial cell lysates. Breast cancer cells expressing high levels of tTgase attached to angiocidin immobilized on tissue culture plates. Angiocidin was a preferred substrate for tTgase forming high molecular weight cross-linked multimers when treated with tTgase. Cross-linked angiocidin contained iso-peptide bonds as demonstrated by Western blotting and immunohistochemical colocalization studies using endothelial cells treated with angiocidin. Cross-linked angiocidin inhibited cell migration in contrast to monomeric angiocidin and inhibited localization of fibronectin (FN), a pro-tumorigenic matrix protein, into the extracellular matrix (ECM) of tumor and HUVE cells. Our studies provide an additional explanation for the anti-tumor activity of angiocidin suggesting that cross-linked angiocidin disrupts the tumor ECM making it less permissive for tumor growth. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931242      PMCID: PMC2815215          DOI: 10.1016/j.yexmp.2009.11.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  42 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Authors:  Yamini Sabherwal; Vicki L Rothman; Ronnie T P Poon; George P Tuszynski
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

3.  The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.

Authors:  T Wakiyama; T Shinohara; T Shirakusa; A S John; G P Tuszynski
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

4.  The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

Authors:  A Gaurnier-Hausser; G P Tuszynski
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 5.  Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer.

Authors:  K Mehta
Journal:  Amino Acids       Date:  2008-07-02       Impact factor: 3.520

Review 6.  Tissue transglutaminase-mediated chemoresistance in cancer cells.

Authors:  Amit Verma; Kapil Mehta
Journal:  Drug Resist Updat       Date:  2007-07-27       Impact factor: 18.500

7.  The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Authors:  Anita Gaurnier-Hausser; Vicki L Rothman; Svetoslav Dimitrov; George P Tuszynski
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 8.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

9.  Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth.

Authors:  Meghan C Brown; Izabela Staniszewska; Luis Del Valle; George P Tuszynski; Cezary Marcinkiewicz
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

10.  Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin.

Authors:  S S Akimov; D Krylov; L F Fleischman; A M Belkin
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

View more
  5 in total

Review 1.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 2.  Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.

Authors:  Kajal Kanchan; Mónika Fuxreiter; László Fésüs
Journal:  Cell Mol Life Sci       Date:  2015-05-06       Impact factor: 9.261

3.  Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

Authors:  X G Guan; X Q Guan; K Feng; R Jian; D Tian; D Tian; H B Tong; X Sun
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 4.  Extracellular TG2: emerging functions and regulation.

Authors:  Alexey M Belkin
Journal:  FEBS J       Date:  2011-11-21       Impact factor: 5.542

5.  Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear factor kappa (NF-ĸB).

Authors:  Jessica Godek; Irene Sargiannidou; Sneha Patel; Lauren Hurd; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2011-01-15       Impact factor: 3.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.